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Abstract: The need for synergy testing is driven by the necessity to extend the antimicrobial spectrum,
reducing drug dosage/toxicity and the development of resistance. Despite the abundance of synergy
testing methods, there is the absence of a gold standard and a lack of synergy correlation among
methods. The most popular method (checkerboard) is labor-intensive and is not practical for clinical
use. Most clinical laboratories use several gradient synergy methods which are quicker/easier to use.
This study sought to evaluate three gradient synergy methods (direct overlay, cross, MIC:MIC ratio)
with the checkerboard, and compare two interpretative criteria (the fractional inhibitory concentra-
tion index (FICI) and susceptibility breakpoint index (SBPI)) regarding these methods. We tested
70 multidrug-resistant Pseudomonas aeruginosa, using a tobramycin and ceftazidime combination.
The agreement between the checkerboard and gradient methods was 60 to 77% for FICI, while
agreements for SBPI that ranged between 67 and 82.86% were statistically significant (p ≤ 0.001).
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1. Introduction 
The emergence of multidrug-resistant (MDR) bacteria is becoming progressively 
more widespread, especially in cystic fibrosis (CF), where persistent colonization of the 
lungs leads to prolonged prophylactic treatment, thereby increasing the likelihood of 
multidrug-resistant organisms [1]. In the CF population, Pseudomonas aeruginosa in 
particular colonizes 70% of CF adults by the age of 25 [2,3]. Therefore, various treatment 
approaches (s ch as combination therapy) are employed in patient management to delay 
the developm nt of resistance to any individual drug during treatment, thus controlling 
the emergence of multidrug-resistant strains [1,4]. In addition, the use of two anti-
pseudomonal agents (for example, β-lactams and aminoglycosides) for combination 
therapy, where ne/both are generally effective, is recommended in the management of 
infective pulmonary exacerbations, due to their synergistic activity [4,5]. However, there 
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1. Introduction
The emergence of multidrug-resistant (MDR) bacteria is becoming progressively more
widespread, especially in cystic fibrosis (CF), where persistent colonization of the lungs
leads to prolonged prophylactic treatment, thereby increasing the likelihood of multidrug-
resistant organisms [1]. In the CF population, Pseudomonas aeruginosa in particular colonizes
70% of CF adults by the age of 25 [2,3]. Therefore, various treatment approaches (such
as combination therapy) are employed in patient management to delay the development
of resistance to any individual drug during treatment, thus controlling the emergence of
multidrug-resistant strains [1,4]. In addition, the use of two anti-pseudomonal agents (for
example, β-lactams and aminoglycosides) for combination therapy, where one/both are
generally effective, is recommended in the management of infective pulmonary exacerba-
tions, due to their synergistic activity [4,5]. However, there is a lack of evidence guiding
the clinician in decisions regarding the best antimicrobial combination that will give a
positive outcome [4,6,7], especially in CF chronic P. aeruginosa infections, where there is
often discordance between susceptibility results and clinical outcome [8]. In the laboratory,
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there is generally the use of several methods that yield inconsistent results [4], and a lack
of accepted standards for in vitro antimicrobial synergy testing. Most methods, such as the
checkerboard and time-kill assay, are well-tested methods for evaluating synergy in vitro,
but they are labor-/time-intensive and are not scalable as a therapeutic tool in clinical mi-
crobiology [9]. To mitigate these issues, the gradient diffusion method has been employed
in clinical microbiology for susceptibility/synergy testing [10]. These gradient diffusion
plastic strips, impregnated with a pre-defined antibiotic concentration gradient, are placed
on a pre-inoculated streaked agar plate, with elliptical inhibition zones as indicators of
minimum inhibitory concentration (MIC) at the intersections of the inhibition zone, and
the strip edge is read following overnight incubation [10]. This provides a rapid, simple,
and accurate method to measure the MIC of antimicrobials and, when adapted for use
in combination, is an equally straightforward method for assessing synergy in clinical
laboratories [10,11]. In practice, several gradient methods, such as the cross (90◦ angle),
direct overlay (fixed ratio), agar diffusion and MIC:MIC method, have been employed for
assessing synergy, but there is currently no consensus on its agreement with any reference
standard in assessing synergy [11,12] in P. aeruginosa.
The Cystic Fibrosis Susceptibility Testing Service (CFASS) performs extended sus-
ceptibility and synergy testing on Gram-negative bacterial isolates recovered from the
respiratory tracts of CF adults in Scotland. At present, the service uses the direct overlay
method to assess the synergy between two antimicrobial agents. The aim of this study
was to compare and correlate three gradient diffusion methods (cross, direct overlay,
and the MIC:MIC method) with a reference method (the checkerboard assay). The agar
dilution method was not included, as it is deemed too labor-intensive for most clinical
laboratories [12]. A secondary objective of this study was to determine the effect of the
interpretative criteria on the observed antimicrobial combination results. Our findings are
expected to provide empirical evidence on the interpretation of combination testing results




During the study period, 70 MDR P. aeruginosa isolates underwent antimicrobial com-
bination testing, using three gradient diffusion methods and the microbroth checkerboard
assay. The interpretative category results were determined, using the gradient and checker-
board assay. Of these, 27.14% (n = 19/70) were susceptible to tobramycin, while none of
the 70 isolates exhibited ceftazidime MIC values in the susceptible range; however, 37.14%
(n = 26/70) were classified as susceptible with increased exposure. The proportion of
isolates that were resistant to both tobramycin and ceftazidime was 47.14% (n = 33/70).
The average strain MIC value was 33.38 mg/L (MIC50 = 3.0 mg/L, MIC90 = 48 mg/L)
and 28.02 mg/L (MIC50 = 4.0 mg/L, MIC90 = 64 mg/L) for the tobramycin gradient and
checkerboard assay, respectively, while 178.04 mg/L (MIC50 = MIC90 ≥ 256 mg/L) and
177.39 mg/L (MIC50 = MIC90 ≥ 256 mg/L) were observed for ceftazidime.
2.1.2. Essential and Categorical Agreement of Single- and Combination-MIC Testing
The essential and categorical levels of agreements for observed MIC values using
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Figure 1 shows that the essenti l greement of the ob aine single- gent MIC values for
tobramyci was 91.43% (n = 64/70) within ≤1 two-fold dilution, while 74.29% (n = 52/70)
was observ d for ceftazidime. Of these, 37.14% (n = 26/70) and 52.86% (n = 37/70) bsolute
agreement was observed for tobramycin and c ftazidime, respectively. Fu ther analysis for
categorical agreement using kappa st tistics showed that the levels of agre ment between
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p ≤ 0.001) was obs rved for c f azidime. Inter stingly, when we an lyzed our synergy
gradien MIC value for g eem nt wi h the checkerb ard as ay, Figure 1 showed that
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there was a reduced essential agreement, in the proportions of isolates for combination
MICs within ≤1 two-fold dilution, for both tobramycin and ceftazidime. While similar
reductions were observed for all tobramycin gradient diffusion methods, the MIC:MIC
method demonstrated the least (~20%) reduction compared with the checkerboard assay
for ceftazidime.
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Figure 1. Proportions of isolates with an essential agreement to the comparator. Measurements are
expressed as relative log differences in gradient MIC values, compared with the checkerboard assay,
for (a) tobramycin and (b) ceftazidime; green bars represent the proportion of isolates with ≤2 log
dilutions, while isolates ≥ 2 log dilutions are represented with blue bars. All experiments were
carried out as triplicates.
2.1.3. FICI and SBPI of P. aeruginosa Isolate Synergy Testing
The combination MIC values from 70 patient-unique P. aeruginosa samples were used
in our evaluation of the three gradient synergy methods, with the checkerboard method as
a comparator. Using the FICI as interpretative criteria (Figure 2), the checkerboard method
produced 28.57% isolates displaying synergy (n = 20) in the study population. Comparison
of the gradient synergy population with the comparator showed a decreas for both the
MIC:MIC (17.14%, n = 12) and direct overlay (8.57%, n = 6) methods, while 60% increase
was observed using the cross method (45.71%, n = 32). In contrast, the comparative analysis
of SBPI values (Figure 2) showed an increase in the proportion of isolates for all three
gradient diffusion methods. The cross method (8.82%, n = 37) produced the least increase,
while direct overlay (47.06%, n = 50) produced the most.
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Figure 2. Observed FICI and SBPI proportions in study isolates. Measurements are expressed as proportions of synergy for
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synergistic (dotted) and poor SBPI values, while no interaction (dotted) and good SBPI values are represented with green
bars. All experiments were carried out as triplicates.
2.1.4. FICI and SBPI Comparator Agreement
We further analyzed our FICI and SBPI data for agreement with the comparator using
Cohen’s kappa statistics. Table 1 showed that, although FICI values had 77.14% (direct
overlay), 71.43% (MIC:MIC) and 60% (cross) categorical agreement, p or kappa statistics
were observed. Of the 20 checkerboard synergistic isolates, the cross method showed 60%
absolute agreem nt, while 25% and 30% were obs rved for the direct overlay and MIC:MIC
methods, respectively (Table 1).
Antibiotics 2021, 10, 967 5 of 12
Table 1. Concordance among the checkerboard and the three gradient diffusion methods, using the
FICI criteria (n = 70).
Checkerboard Categorical Kappa Statistics
Gradient Method Synergy Indifference Total Agreement (%) K p-Value
Cross 60.00 0.169 0.129
Synergy 12 20 32
Indifference 8 30 38
Direct overlay 77.14 0.291 0.002
Synergy 5 1 6
Indifference 15 49 64
MIC:MIC 71.43 0.205 0.071
Synergy 6 6 12
Indifference 14 44 58
In contrast, Table 2 shows that a statistically significant categorical agreement was
observed, using the SBPI criteria, for all gradient methods. The highest level of agreement
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among methods. The most popular method (checkerboard) is labor-intensive and is not practical for 
clinical use. Most clinical laboratories use several gradient synergy methods which are 
quicker/easier to use. This study sought to evaluate three gradient synergy methods (direct overlay, 
cross, MIC:MIC ratio) with the checkerboard, and compare two interpretative criteria (the fractional 
inhibitory concentration index (FICI) and susceptibility breakpoint index (SBPI)) regarding these 
methods. We tested 70 multidrug-resistant Pseudomonas aeruginosa, using a tobramycin and 
ceftazidime combination. The agreement between t e checkerboard and gradient methods was 60 
to 77% for FICI, while agr ements for SBPI that rang d between 67 nd 82.86% were statistically 
significant (p ≤ 0.001). High kappa greem nts were observed using SBPI Ƙ > 0.356) compared to 
FICI (Ƙ < 0.291) criteria, and the MIC:MIC method demonstrated the highest, albeit moderate, 
intraclass correlation coefficient (ICC = 0.542) estimate. Isolate resistance profiles suggest method-
dependent synergism for isolates, with ceftazidime susceptibility after increased exposure. The 
results show that when interpretative criteria are considered, gradient diffusion (especially 
MIC:MIC) is a valuable and practical method that can inform the treatment of cystic fibrosis patients 
who are chronically infected with P. aeruginosa. 
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1. Introduction 
The emergence of multidrug-resistant (MDR) bacteria is becoming progressively 
more widespread, especially in cystic fibrosis (CF), where persistent colonization of the 
lungs leads to prolonged prophylactic treatment, thereby increasing the likelihood of 
multidrug-resistant organisms [1]. In the CF population, Pseudomonas aeruginosa in 
particular colonizes 70% of CF adults by the age of 25 [2,3]. Therefore, various treatment 
approaches (such as combination therapy) are employed in patient management to delay 
the development of resistance to any individual drug during treatment, thus controlling 
the emergence of multidrug-resistant strains [1,4]. In addition, the use of two anti-
pseudomonal agents (for example, β-lactams and aminoglycosides) for combination 
therapy, where one/both are generally effective, is recommended in the management of 
infective pulmonary exacerbations, due to their synergistic activity [4,5]. However, there 
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= 0. 56, p < 0.001). Inter stingly, for indices < 2.0,
there was ≈88–91% agreemen among the three gradient methods. However, marked
differences ere ob erv d in the SBPI 2–50 range, with the cross (80%) and MIC:MIC
(68.57%) methods showing the highest agr ement. The l west l vel of agreement (45.71%)
was shown using the dir ct overlay method.
Table 2. Concordance among the checkerboard and the three gradient diffusion methods, using the SBPI criteria (n = 70).
Checkerboard Categorical Kappa Statistics
Gradient Method 0–2 2–50 50–100 >100 Total Agreement (%) K p-Value
Cross 82.86 0.662 <0.001
0–2 30 7 0 0 37
2–50 4 28 0 1 33
50–100 0 0 0 0 0
>100 0 0 0 0 0
Direct overlay 67.14 0.356 0.001
0–2 31 19 0 0 50
2–50 3 16 0 1 20
50–100 0 0 0 0 0
>100 0 0 0 0 0
MIC:MIC 77.14 0.556 <0.001
0–2 30 10 0 0 40
2–50 4 24 0 1 29
50–100 0 1 0 0 1
>100 0 0 0 0 0
Interestingly, when we used the intraclass correlation coefficient to evaluate the
strength of the comparator relationship in method-derived synergy MIC values, moderate
ICC estimates of 0.542, with a 95% confidence interval from 0.469 to 0.607 (F(419) = 3.424,
p < 0.001), were observed using the MIC:MIC method, whi e the cro s and direct overlay
methods both produced poor ICC estimates (Tab e 3).
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Table 3. Intraclass coefficient analysis of gradient diffusion methods, using an absolute agreement, two-way mixed model.
Intraclass 95% Confidence Interval F Test with True Value 0
Method Correlation Lower Bound Upper Bound Value df1 df2 p-Value
Cross 0.386 0.302 0.465 2.280 419 419 <0.001
Direct Overlay 0.259 0.165 0.347 1.743 419 419 <0.001
MIC:MIC 0.542 0.469 0.607 3.424 419 419 <0.001
2.1.5. Effect of Resistance Profiles on FICI and SBPI Values
Finally, we analyzed our data to understand the effect of resistance profiles on the
FICI and SBPI values. Table 4 shows that the cross method overpopulated synergy for all
resistant profiles except the tobramycin-susceptible isolates. In contrast, low synergism
was observed for those isolates with profiles of ceftazidime susceptibility after increased
exposure using the direct overlay and MIC:MIC methods. Indeed, our data showed
that, for these isolates, a discordant synergy result (0–67%) was observed for all methods.
Interestingly, the SBPI analysis showed that the direct overlay method produced more
isolates with low SBPI values for ceftazidime-resistant isolates. In addition, a pairwise
comparator comparison (Table 4) showed that, of the synergy observed in 7/33 tobramycin-
and ceftazidime-resistant isolates, a 57.14% (n = 4/7) agreement was observed using the
direct overlay and cross method, while only 28.57% (n = 2/7) was observed for MIC:MIC.
In contrast, the resistance profile did not affect comparator agreement, as high proportions
were observed for SBPI values < 2.0.
Table 4. Effect of resistance profile on FICI and SBPI values in the study population.
Gradient Diffusion Method % a (No. of
Isolates) b
Comparator Agreement % a (No.
of Isolates) b
Resistance Profile No * Index Result CB £ Cross DO £ MIC:MIC Cross DO £ MIC:MIC
TM (R #) TZ (R #) 33 FICI Syn $ 21.21 (7) 33.33(11) 15.15 (5) 18.18 (6) 57.14 (4) 57.14 (4) 28.57 (2)




















2.0–50.00 36.36 (12) 21.21 (7) 3.03 (1) 24.24 (8) 50.00 (6) 8.33 (1) 50.00 (6)
TM (R #) TZ (I #) 18 FICI Syn $ 27.78 (5) 66.67(12) 5.56 (1) 5.56 (1)
100.00
(5) 20.00 (1) 20.00 (1)


















2.0–50.00 33.33 (6) 44.44 (8) 38.89 (7) 16.67 (3) 100.00(6) 66.67 (4) 33.33 (2)
TM (S #) TZ (R #) 11 FICI Syn $ 45.45 (5) 36.36 (4) 0(0) 45.45 (5) 20.00 (1) 0(0) 60.00 (3)
NI $ 54.55 (6) 63.64 (7) 100.00(11) 54.55 (6) 50.00 (3)
100.00
(6) 66.67 (4)
SBPI ≤2.0 9.09 (1) 0(0) 45.45 (5) 0(0) 0(0) 100.00(1) 0(0)







TM (S #) TZ (I #) 8 FICI Syn $ 37.50 (3) 62.50 (5) 0(0) 0(0) 66.67 (2) 0(0) 0(0)







SBPI ≤2.0 0(0) 12.50 (1) 25.00 (2) 12.50 (1) 0(0) 0(0) 0(0)
2.0–50.00 100.00 (8) 87.50 (7) 75.00 (6) 87.50 (7) 87.50 (7) 75.00 (6) 87.50 (7)
# M, tobramycin; TZ, ceftazidime; R, resistant; I, susceptible after increased exposure; S, susceptible; * total number of isolates in the
resistance profile; $ Syn, synergistic; NI, no interaction; £ CB, checkerboard; DO, direct overlay; a proportion of isolate; b number of isolates.
3. Discussion
In CF patient management, there is the continuous emergence of multi-/pan-drug-
resistant (MDR/PDR) strains, especially Pseudomonas aeruginosa, due to the prolonged and
frequent administration of antimicrobial agents that are used in the treatment of pulmonary
exacerbations [1,2,4,5]. The emergence of these MDR/PDR phenotypes, resistant to several
Antibiotics 2021, 10, 967 7 of 12
classes of antimicrobials, impacts the therapeutic options in clinical practice [13]. As a result,
in chronic pulmonary exacerbations management, physicians are compelled to employ
combination therapy using ≥2 antibiotics, of which the inhibitory effects of the antibiotics
used together are greater than the sum of each agent’s activity in monotherapy [14]. There
is a dearth of evidence on the best antimicrobial combination that will give a positive
outcome [4,6,7,13] in clinical management, as the response of P. aeruginosa to various
antimicrobial combinations has been shown to be unpredictable [11]. This is further
confounded by the lack of in vitro synergy testing standardization, and the absence of gold
standards. Kidd et al. [14] reported that disk and gradient diffusion tests are mostly used
in clinical microbiology laboratories, due to their low cost and ease of performance, while
dilution tests are commonly employed in research and reference laboratory settings. In this
study, we compared the performance of three gradient diffusion tests for synergy testing
to the checkerboard micro broth dilution method. We chose ceftazidime and tobramycin
combinations as the evaluated antimicrobial combinations, as this treatment is commonly
used in the management of CF-MDR P. aeruginosa pulmonary exacerbations [5] and has
been previously described as producing synergistic interactions [15].
In this study, as described in previous studies [12,16], our data suggest that the ob-
served single-agent gradient MIC results correlated well (>82% categorical agreement) with
those values obtained using the checkerboard assay. Lasko et al. [16] recently demonstrated
that at least an 80% categorical agreement was observed in a comparative analysis of the gra-
dient method vs. the broth microdilution assays for ceftazidime, ceftolozane/tazobactam,
meropenem and tobramycin in CF-derived P. aeruginosa. Similarly, in agreement with
Pankey et al. [12], the median single-agent MIC values were at ≤1 two-fold dilution for
both methods and antimicrobials. These levels of agreement and the ease of performance
lend credence to the potential of gradient diffusion methods for evaluating in vitro antimi-
crobial synergy. There is currently no clear consensus on the gold standard for method
evaluation, and no agreement exists on the best method. Several methods have been
described and evaluated, for agreement with checkerboard or time-kill assays, as refer-
ence standards using numerous bacteria/antimicrobial combinations [13]. The time-kill
method has been shown to yield high concordance in various studies, but because it pro-
duces dynamic and longitudinal information that cannot be obtained by other methods,
its use as the gold standard for synergy testing is debatable [17]. In contrast, the broth
microdilution assay and the gradient synergy method measure the inhibitory activities of
antibiotics [12]. Therefore, we used the checkerboard assay to assess the levels of synergy
observed for each gradient method. Mirrored in our data, as described by other synergy
studies [12,18], is the observation that the gradient direct overlay method tends to show
the effects of the most active agent, rather than the interactions between both agents, and
often underestimates synergism. However, unlike Balke et al. [18], we observed lower
synergy proportions; a plausible explanation of the difference might be the study isolate
population, since their study was composed of 71% tobramycin-susceptible strains, thus
increasing the synergy rates. Indeed, we demonstrate a method-dependent synergism
using isolates with resistance profiles of ceftazidime susceptibility after increased expo-
sure. In addition, our data (Supplemental File) reveals statistically significant differences
when tobramycin gradient strips were placed before ceftazidime strips, suggesting that
an antibiotic-dependent effect might be responsible for the inconsistencies. We propose
that further research should be explored to enrich our understanding of antibiotics syn-
ergy testing. A plethora of evidence suggests several mechanisms of resistance, such as
the presence of mobile plasmid-borne β-lactamase genes, as well as changes in the cell
outer membrane through the decrease in the number of porins present and mutations that
change the selectivity of porin channels [19,20]. Other mechanisms affecting drug uptake
are the possession of chromosomal-encoded genes for efflux pumps that can be expressed
(constitutively induced) or overexpressed modifications in the 30S and 50S ribosomal
subunits [19,20]. Although not a remit of this study, the molecular characterization of study
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isolates would enrich our knowledge on the impact of resistant markers on antimicrobial
uptake during synergy testing.
There is growing interest in understanding the unpredictability of synergy results.
Gómara et al. [13] reported that, depending on the mathematical model, drug interactions
can lead to opposite conclusions with the lack of translation, due to the use of MIC as the
basis for calculation. Hence, the standard reference parameter (FICI) for quantification of
pairwise drug interactions was modified to more restrictive criteria, where synergy was
described as a ≥four-fold reduction in the MICs of both compounds when in combination,
compared with their MICs alone [13,21]. Despite these restrictive criteria, there is still an
absence of consensus and standardization in synergy studies. Hence, our lab proposed the
use of SBPI as a useful parameter for comparing the in vitro effectiveness of antimicrobial
combinations. Milne et al. [15] proposed that this parameter, defined as the summation of
inverse proportions of the organisms’ susceptible breakpoint and the combination’s MIC,
might be useful in assessing the outcome of antimicrobial combination testing. Indeed,
our results present strong in vitro evidence that SBPI has the potential to remove the
unpredictability associated with the FICI criteria, notwithstanding the need for outcome
studies to evaluate the efficacy of synergy testing in the CF population. However, Aaron
et al. [6], in a 4.5-year, randomized, double-blind controlled study involving 132 patients,
concluded that there was no difference in the lung function, dyspnea, bacterial density
or treatment failure in the study cohort of patients who were treated with the multiple-
combination bacterial antimicrobial testing. While results from this study are disappointing
because of the disagreements between different methods and the uncertainty of the FICI
criteria, we propose that a holistic approach involving several synergy methods and
interpretative criteria should be explored in clinical trials, to unravel synergy testing.
Limitations of this study include the choice of microorganism and/or antimicrobial
agents, single-rater analyses, and test concentrations and the use of the highest doubling
dilution of antimicrobials above those used in clinical practice.
Although it is difficult to conclusively demonstrate the absolute advantages of each
synergy method/interpretative criterion, this research reiterates the need for clinical mi-
crobiology laboratories to standardize synergy testing, and for setting up a single clear
definition for synergy/clinical relevance. It also gives empirical in vitro evidence that
SBPI should be further explored as the interpretative criterion, due to the uncertainties
associated with the FICI criterion. Finally, due to synergy under- and overpopulation
using the direct overlay and cross methods, respectively, the results suggest the adoption
of the MIC:MIC as the preferred method for studying antibiotic interactions in diagnostic
samples.
4. Materials and Methods
4.1. Study Isolates and Media
Of the 721 MDR P. aeruginosa sent to CFASS for extended antimicrobial susceptibility
testing over a 20-year period (2001–2020), one-tenth of the patient-unique isolates were
randomly selected for this study. These isolates, stored in the bacterial preservation system
MICROBANKTM (Pro-Lab Diagnostics, Richmond Hill, ON, Canada) at −80 ◦C, were
plated onto Mueller-Hinton (MH) agar (Oxoid Ltd., Basingstoke, UK) and were identified
using a Vitek® MS (BioMérieux, Inc., Durham, NC, USA). Isolates were tested by CFASS
and were classified as multidrug-resistant if there was acquired non-susceptibility to at
least one agent in the ≥3 antimicrobial group [22]. The media used for minimum inhibitory
concentration (MIC) and synergy testing included Mueller-Hinton agar and cation-adjusted
Mueller-Hinton II broth (CAMHB). P. aeruginosa ATCC 27853 was used as a quality control
strain to validate the MIC values.
4.2. Antimicrobial Agents
Standard laboratory powders of an aminoglycoside, tobramycin (TM) and a β-lactam,
ceftazidime (TZ) hydrate (both manufactured by Sigma-Aldrich, St Louis, MO, USA) were
Antibiotics 2021, 10, 967 9 of 12
used for the checkerboard experiments. For the gradient diffusion experiments, test strips
(BioMérieux, Basingstoke, UK) of both antimicrobial agents were used, according to the
manufacturer’s instructions.
4.3. Gradient Diffusion MIC Testing
The MICs for each isolate were determined, using TM and TZ gradient test strips.
Briefly, a saline suspension of 0.5 McFarland standard (1.0 for mucoid strains) from 24-
hour cultures was inoculated onto MH agar, according to the EUCAST guidelines for
disk diffusion plate inoculation [15]. Two gradient test strips (TM and TZ) were placed
top-to-tail, according to the manufacturer’s instructions. These plates were incubated
in ambient air at 35 ◦C for 18 ± 2 h. After incubation, the MIC values were read at
ellipse intersections of the MIC reading scale. MICs were interpreted as susceptible (S),
susceptible with increased exposure (I) (intermediate resistance), or resistant (R), based on
the guidelines published by European Clinical Antimicrobial Susceptibility Testing [23].
MIC values for all isolates were obtained as the mean MIC of three independent biological
replicates. Categorical agreement was defined as an agreement of interpretative results
(SIR) with the comparator, while essential agreement was defined as an agreement within
±1 two-fold dilution with the reference standard [24,25]. The MICs of the antimicrobials
that inhibited 50% and 90% of the isolates were calculated and expressed as MIC50 and
MIC90, respectively.
4.4. Gradient Diffusion Synergy Methods
Assessment of the synergy methods was carried out for each method using three
biological replicates, according to the methods employed by Pankey et al. [12]. As de-
scribed, bacterial suspensions of each isolate were prepared in a saline solution adjusted
to 0.5 McFarland standard, and an even lawn was spread onto MH agar. The placement
of the gradient test strip was different for each method. The combination MIC was read
after 18 ± 2 h incubation in ambient air at 35 ◦C and interpreted as the value at which the
inhibition zone intersected the scale on each respective gradient diffusion strip.
4.4.1. Cross Method
Test strips for antimicrobials TM and TZ were placed on the inoculated 90 mm MH
agar plate in a cross formation, with a 90◦ angle at the intersection between the scales at
their previously determined respective MICs.
4.4.2. Direct Overlay Method
TM and TZ test strips were placed top-to-tail on different sections of a 90-mm MH
agar and incubated at room temperature. After 1 h, to allow for antimicrobial diffusion
into the agar, the test strips were removed and discarded. A fresh test strip of the opposite
antimicrobial was placed directly over the imprint of the first antimicrobial (i.e., the TM
strip was replaced with a fresh TZ strip, and vice versa).
4.4.3. MIC:MIC Overlay Method
TM and TZ strips were placed on different sections of a 150-mm MH agar plate. The
agar was marked with an inoculating loop adjacent to the previously determined MIC
value for each strip. For isolates where the MIC exceeded the concentration on the test strip,
the highest concentration was marked on the agar. The strips were removed and discarded
after 1 h incubation at room temperature, to enable the antimicrobials to diffuse into the
agar. A fresh opposite test strip was placed over the imprint of the discarded strip so that
the MIC of the fresh strip lined up with the mark that signified the MIC of the discarded
strip.
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4.5. Broth Microdilution Checkerboard Method
To validate the synergy results, checkerboard assays were performed on the isolates
according to Leber et al. [26]. Briefly, 24-hour isolates were inoculated into CAMHB, and
incubated at 35 ◦C until the exponential growth phase. Using a 96-well plate, a two-fold
dilution of freshly prepared antimicrobial at different concentrations was dispensed in a
checkerboard array and inoculated with 105 CFU/ml of bacterial suspension. One well
with no antibiotics was used as the positive control. After incubation at 35 ◦C, plates were
examined for visual turbidity using the magnifying mirror reader; growth was indicated
as turbidity in wells. The MIC value was derived as the lowest drug concentration with no
visible growth [27,28]. MIC values for all isolates were obtained as the mean MIC of three
independent biological replicates.
4.6. Interpretative Criteria
4.6.1. Fractional Inhibitory Concentration Index (FICI)
The synergy MIC was expressed using the FICI and calculated as described below.
FICI = (MIC A combination/MIC A single) + (MIC B combination/MIC B single)
If the MIC value was greater than the antimicrobial range tested, the next doubling
dilution above this value was used to calculate the FICI (e.g., if an MIC of >32 mg/L was
found, then the FICI was calculated using 64 mg/L) [29]. These indices were interpreted as
synergy (FICI ≤ 0.5), no interaction (FICI > 0.5 and ≤4.0) and antagonism (FICI > 4.0) [21].
4.6.2. Susceptible Breakpoint Index (SBPI)
The SBPI was used to describe synergy analysis and calculated as described below.
SBPI = (susceptible breakpoint of antimicrobial A/MIC of antimicrobial A combina-
tion) + (susceptible breakpoint of antimicrobial B/MIC of antimicrobial B combination) [15].
These combination results were categorized in rank order, according to their decreasing
SBPI results. Values were interpreted as poor for values < 2, good for 2–50, and very good
for 50–100, while >100 was exceptional.
4.7. Statistical Analysis
Statistical analyses of the categorical and continuous variables were carried out using
Microsoft Office Excel 2013 and IBM SPSS Statistics for Windows, Version 25 (IBM Corp.,
Armonk, NY, USA). Categorical agreement of FICI and SBPI values was determined
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0.75, wh le values between 0.40 and 0.75 were classified
as g od [12]. A p-valu of <0.05 was c ns d red statistically s gnificant. All numerical
gradient-derived synergy MIC valu w r used to cal ul te the intraclass correlation
co fficient (ICC) estima es and their 95% co fiden int rvals, using an SPSS based on a
si gle-rati g, absolute agreement, two-way mixed-effects model. ICC values of less than
0.5 were indicativ of poor reliability, 0.5–0.75, moderate reliability, and 0.75–0.90, good
reliability, while values greater than 0.90 were indicative of excellent reliability [30].
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